Legend Biotech USA Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2037
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 19, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 21, 2026
- Oct 20 US 12,766,192 Antibodies and Chimeric Antigen Receptors Targeting GLYPICAN-3 (GPC3) and Methods of Use Thereof
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,934,363 | Chimeric Antigen Receptors Based on Single-Domain Antibodies and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,351,638 | Chimeric Antigen Receptors Targeting Bcma and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,186,647 | Chimeric Antigen Receptors Targeting Bcma and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,535,677 | Chimeric Antigen Receptors Targeting Bcma and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,522,645 | Bcma-Targeted Car-T Cell Therapy of Multiple Myeloma In force · High confidence | In force | High confidence | |
| US 12,097,219 | Single-Domain Antibodies Against CLL1 and Constructs Thereof In force · High confidence | In force | High confidence | |
| US 12,275,788 | Single-Domain Antibodies Against CD33 and Constructs Thereof In force · High confidence | In force | High confidence | |
| US 12,590,166 | CD20 Binding Molecules and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,703,759 | CD19 Binding Molecules and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,766,192 | Antibodies and Chimeric Antigen Receptors Targeting GLYPICAN-3 (GPC3) and Methods of Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 10: 1 patent in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending